Randomized phase III TRIAL COMPARING FOLFIRINOX (F: 5FU/LEUCOVORIN [LV], IRINOTECAN [1], AND OXALIPLATIN [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial

被引：29
|
作者：
Conroy, T.
Desseigne, F.
Ychou, M.
Ducreux, M.
Bouche, O.
Guimbaud, R.
Becouarn, Y.
Montoto-Grillot, C.
Gourgou-Bourgade, S.
Adenis, A.
机构：
[1] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[2] Ctr Leon Berard, F-69373 Lyon, France
[3] Ctr Val Aurelle, Montpellier, France
[4] Inst Gustave Roussy, Villejuif, France
[5] Univ Hosp Robert Debre, Reims, France
[6] Univ Hosp Purpan, Toulouse, France
[7] Inst Bergonie, Bordeaux, France
[8] Federat Natl Ctr Lutte Canc, Paris, France
[9] Ctr Oscar Lambret, F-59020 Lille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4010
引用
收藏
页数：1
相关论文
共 35 条
  • [1] FINAL RESULTS OF A RANDOMIZED PHASE III TRIAL COMPARING FOLFIRINOX (F: 5FU/LEUCOVORIN [LV], IRINOTECAN [I] AND OXALIPLATIN [O]) VS GEMCITABINE (G) AS FIRST-LINE TREATMENT FOR METASTATIC PANCREATIC ADENOCARCINOMA (MPA). THE PRODIGE 4/ACCORD 11 TRIAL
    Desseigne, F.
    Ychou, M.
    Ducreux, M.
    Bouche, O.
    Guimbaud, R.
    Becouarn, Y.
    Montoto-Grillot, C.
    Gourgou-Bourgade, S.
    Adenis, A.
    Conroy, T.
    ANNALS OF ONCOLOGY, 2010, 21 : 251 - 251
  • [2] Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial
    Ychou, M.
    Desseigne, F.
    Guimbaud, R.
    Ducreux, M.
    Bouche, O.
    Becouarn, Y.
    Adenis, A.
    Montoto-Grillot, C.
    Luporsi, E.
    Conroy, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (GONO).
    Falcone, A.
    Masi, G.
    Brunetti, I.
    Benedetti, G.
    Bertetto, O.
    Picone, V.
    Chiara, S.
    Merlano, M.
    Vitello, S.
    Ricci, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 149S - 149S
  • [4] Biweekly irinotecan, oxaliplatin and infusional 5FU/LV (FOLFOXIRI) versus folfiri as first-line treatment of metastatic colorectal cancer (MCRC):: Results of a randomized phase III trial by the gruppo oncologico nord ovest (GONO)
    Masi, G.
    Allegrini, G.
    Brunetti, I.
    Murr, R.
    Ricci, S.
    Benedetti, G.
    Crino, L.
    Fanchini, L.
    Bertetto, O.
    Picone, V.
    Cortesi, E.
    Vitello, S.
    Chiara, S.
    Rosso, R.
    Granetto, C.
    Merlano, M.
    Porcile, G.
    Alabisio, O.
    Fioretto, L.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2005, 16 : 7 - 7
  • [5] A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer
    Boukovinas, I.
    Androulakis, N.
    Polyzos, A.
    Vardakis, N.
    Amarantidis, K.
    Bozionelou, V.
    Kouroussis, C.
    Giassas, S.
    Christophyllakis, C.
    Mavroudis, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2+/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49
    Pernot, Simon
    Pellerin, Olivier
    Mineur, Laurent
    Monterymard, Carole
    Smith, Denis
    Lapuyade, Bruno
    Gallois, Claire
    Tougeron, David
    Thirot-Bidault, Anne
    Audemar, Franck
    Simon, Mireille
    Lecaille, Cedric
    Louafi, Sami
    Lepage, Come
    Ducreux, Michel
    Taieb, Julien
    Akouz, Faiza Khemissa
    De Baere, Thierry
    DIGESTIVE AND LIVER DISEASE, 2022, 54 (03) : 324 - 330
  • [7] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC): A PHASE II TRIAL BY THE GONO GROUP
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Salvatore, L.
    Fornaro, L.
    Baldi, G.
    Stasi, I
    Cupini, S.
    Ciarlo, A.
    Del Monte, F.
    Trenta, P.
    Mezi, S.
    Rondini, M.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 12 - 12
  • [8] A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
    Stathopoulos, G. P.
    Syrigos, K.
    Aravantinos, G.
    Polyzos, A.
    Papakotoulas, P.
    Fountzilas, G.
    Potamianou, A.
    Ziras, N.
    Boukovinas, J.
    Varthalitis, J.
    Androulakis, N.
    Kotsakis, A.
    Samonis, G.
    Georgoulias, V.
    BRITISH JOURNAL OF CANCER, 2006, 95 (05) : 587 - 592
  • [9] A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
    G P Stathopoulos
    K Syrigos
    G Aravantinos
    A Polyzos
    P Papakotoulas
    G Fountzilas
    A Potamianou
    N Ziras
    J Boukovinas
    J Varthalitis
    N Androulakis
    A Kotsakis
    G Samonis
    V Georgoulias
    British Journal of Cancer, 2006, 95 : 587 - 592
  • [10] Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)
    Aparicio, T.
    Lavau-Denes, S.
    Phelip, J. M.
    Maillard, E.
    Jouve, J. L.
    Gargot, D.
    Gasmi, M.
    Locher, C.
    Adhoute, X.
    Michel, P.
    Khemissa, F.
    Lecomte, T.
    Provencal, J.
    Breysacher, G.
    Legoux, J. L.
    Lepere, C.
    Charneau, J.
    Cretin, J.
    Chone, L.
    Azzedine, A.
    Bouche, O.
    Sobhani, I.
    Bedenne, L.
    Mitry, E.
    ANNALS OF ONCOLOGY, 2016, 27 (01) : 121 - 127
1234